Attacking the common cold by unshielding its genome

Attacking the common cold by unshielding its genome

The common cold is something that strikes down everyone at some point and it's reported to cost the world economy billions every year due to physician visits and missed days of work.

Professor Ed Tate, who led the research, said: "A drug like this could be extremely beneficial if given early in infection, and we are working on making a version that could be inhaled, so that it gets to the lungs quickly".

The cure for the common cold has been niggling scientists like a tickly throat for decades, but after many long winters searching for a viable treatment, a team of UK-based researchers might have finally made a massive breakthrough.

There are hundreds of variants of the rhinovirus, so attempts to develop vaccines against the common cold have so far failed.

But the new approach could be more successful because it does not target the virus directly.

Researchers at Imperial College in London are developing a way to outsmart the common cold virus by using a molecule that doesn't target the virus at all.

This approach is also advantageous as the virus can not develop resistance when the drug only affects the human protein, added the researchers. The researchers believe that it could work against other related viruses, including those responsible for polio and foot-and-mouth disease. In vitro testing using human cells found the new molecule completely blocked the replication of several cold virus strains.

NASA's next Mars rover mission to carry tiny helicopter
Mars's atmosphere is so thin that hovering just 10 feet above the surface is the equivalent of soaring 100,000 feet above Earth. On its first flight, the helicopter will make a short vertical climb to 3 metres where it will hover for about 30 seconds.

Although dealing with a cold is not a huge issue for most people, there are good reasons to keep hunting for ways to fight it.

This article has been republished from materials provided by Imperial College London.

The results of the first tests were published today in the journal Nature Chemistry.

In particular, rhinoviruses are known to be the cause of acute upper respiratory tract infections and the common cold, in addition to worsening conditions like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

The research showed that this molecule is over 100 times more potent than previous molecules targeting the protein in humans.

They screened a large volume of different compounds looking for a molecule that specifically targeted NMT.

The researchers have high hopes for the drug, which now goes under the codename of IMP-1088.

Related Articles